Valuations in the listed API space have experienced huge price corrections, making them appear attractive, according to Cyndrella Carvalho, Vice President - Healthcare/Pharma Lead, Institutional Research, JM Financial. However, Carvalho added that one or two more quarters are needed for supplies to normalize in the API market to give a clearer understanding of the supply-demand scenario.